antibody-drug conjugate

NH-bis(C1-Boc) is an uncleavable linker used for antibody-drug conjugates (ADC).

DM1-SMe (DM1-SSMe) is a potent inhibitor of maytansinoid microtubular. DM1-SMe is about 3 to 10-fold more potent than the parent drug Maytansine, with IC50s of 0.003 to 0.01 nM for DM1-SMe in a panel of human tumor cell lines.

Datopotamab deruxtecan (DS-1062) is a trophoblast cell surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC) with antitumor activity. Datopotamab deruxtecan induces significant antibody-dependent cellular cytotoxicity in the presence of peripheral blood lymphocytes and inhibits tumor growth in xenograft models.

Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd). Trastuzumab deruxtecan has an improved effect on the treatment of HER2-positive breast cancer and gastric cancer.

Disitamab vedotin (RC-48) is a newly developed antibody-active molecule conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), consisting of Disitamab coupled to monomethyl auristatin E (MMAE) via a cleavable linker. Disitamab vedotin showed anti-tumor and anti-proliferative activities in gastric cancer cells with different HER-2 expression levels and inhibited the expression of HER-2 protein in gastric cancer cells.

Sacituzumab govitecan (IMMU-132) is a humanized ADC compound targeting Trop-2 with anticancer activity for the study of refractory, locally advanced or metastatic breast cancer and uroepithelial cancer.

DSS Crosslinker is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). It is a homobifunctional crosslinker that is cell membrane permeable, with amine-reactive NHS esters at both ends of an 8-atom [11.4 angstrom] spacer arm for conjugating proteins, including intracellular proteins.

Boc-NH-PEG4-CH2COOH is a cleavable ADC linker utilized in the development of antibody-drug conjugates (ADC)[1].

DSG Crosslinker, a cleavable ADC linker, is utilized in the synthesis of antibody-drug conjugates (ADCs).

DSP Crosslinker, used in antibody-drug conjugates (ADCs) synthesis, is a cleavable ADC linker[1].

Fmoc-8-amino-3,6-dioxaoctanoic acid (Fmoc-NH-PEG2-CH2COOH) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) and a PEG-based PROTAC linker for the synthesis of PROTACs.

N-Hydroxysulfosuccinimide sodium is a non-cleavable ADC linker used in antibody-drug conjugates (ADCs) synthesis.

Boc-Val-Cit-OH is a cleavable ADC linker utilized in the synthesis of antibody-drug conjugates (ADCs).

Fmoc-Gly-Gly-OH, a cleavable ADC linker, can be used in the synthesis of antibody-drug conjugates (ADCs).

Succinic anhydride is a cyclic anhydride. Succinic anhydride acts as a nonclaevable ADC linker. Succinic anhydride can react with compound 4 to link the prodrug to an amine or hydroxy 1 group of a targeting polypeptide.

Fmoc-Lys-OH hydrochloride is an alkyl-chain-based PROTAC linker and a non-cleavable ADC linker utilized in the synthesis of antibody-drug conjugates (ADCs).

SMCC (N-Succinimidyl 4-(N-maleimidomethyl)cycl) is a heterobifunctional protein crosslinker.

Boc-C16-COOH is a alkyl-chain-based PROTAC linker. Boc-C16-COOH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

DTSSP Crosslinker, a cleavable ADC linker, is utilized in the synthesis of antibody-drug conjugates (ADCs).

Rinatabart sesutecan is a highly homogeneous antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα). Rinatabart sesutecan consists of a humanized antibody targeting FRα, a hydrophilic cleavable linker, and the topoisomerase I inhibitor eribulin as the payload. It is primarily used for the targeted treatment and mechanistic research of folate receptor-positive solid tumors.

Sacituzumab tirumotecan (SKB264) is an antibody-drug conjugate (ADC) targeting TROP2 (trophoblast cell surface antigen 2), capable of releasing the active payload KL610023 within TROP2-positive tumour cells. an effective topoisomerase I inhibitor that induces DNA damage and leads to cell cycle arrest and apoptosis, for use in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).

ABBV-706 is an antibody-drug conjugate (ADC) that targets the receptor tyrosine kinase SEZ6. After binding to the surface of tumor cells, it is internalized and releases a cytotoxic payload, thereby inducing tumor cell death. ABBV-706 is currently in clinical development and has demonstrated potential antitumor activity in solid tumors such as small cell lung cancer.

Izeltabart Tapatansine (IMGC-936) is a CHO-expressing humanized next-generation medetonin-based ADC compound targeting ADAM9-expressing tumors, and exhibits cytotoxicity against ADAM9-positive human tumor cell lines for cancer research.

Fmoc-Ala-Ala-Asn(Trt)-OH, a cleavable linker essential in ADC (Antibody-Drug Conjugate) synthesis, facilitates the attachment of cytotoxic drugs to antibodies for precise delivery to targeted cells or proteins. Its cleavable properties ensure controlled drug release, thereby optimizing the efficacy of the ADC.